Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Hwanin Pharma - LARVOL DELTA

The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. (PubMed, BMC Psychiatry) - "Holistically considering each endpoint and corresponding "time window", certain SGAs appeared to be efficient augmentation to anti-depressants for TRD, but aripiprazole was relatively more effective and better tolerated."

Clinical • Journal • CNS Disorders • Depression • Mood Disorders • Psychiatry

ESG-1-60 and ESG-1-61: Novel dopamine D3 receptor-preferring partial agonists/antagonists that inhibit cocaine taking and seeking in rodents. (PubMed, Br J Pharmacol) - "Novel D3 receptor-preferring compounds ESG-1-60 and ESG-1-61 were highly effective in reducing cocaine-taking and cocaine-seeking, under various reinforcement conditions. ESG-1-60 warrants further investigation as a new pharmacotherapy for treating cocaine use disorder as it is effective in these models and lacks unwanted behavioural effects."

Journal • Preclinical

Third-Generation Antipsychotics: The Quest for the Key to Neurotrophism. (PubMed, Life (Basel)) - "While second-generation antipsychotics (SGAs) are associated with a better side effect profile than their predecessors, the emergence of third-generation antipsychotics (TGAs)-such as brexpiprazole, cariprazine, lurasidone, iloperidone, lumateperone, pimavanserin, and roluperidone-has prompted renewed interest in their potential neuroprotective and pro-cognitive effects. Although data remain limited and focused primarily on earlier SGAs, emerging findings suggest that some TGAs may exert positive effects on neuroplastic processes, including the modulation of brain-derived neurotrophic factors (BDNFs) and synaptic architecture. However, robust clinical data on their long-term effects and comparative efficacy are lacking; therefore, further research is necessary to validate their role in preventing neurodegenerative changes and improving cognitive outcomes in patients with psychiatric conditions."

Journal • Review • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia • BDNF

Global Trends in the Use of Pharmacotherapy for the Treatment of Bipolar Disorder. (PubMed, Curr Psychiatry Rep) - "Mood stabilizing anticonvulsants like valproate and carbamazepine continue to be vital alternatives, each with distinct side effect profiles necessitating careful patient monitoring. The approval and increasing use of novel atypical antipsychotics, such as lurasidone (2013) and cariprazine (2015), has expanded treatment options, offering efficacy in different phases of BD with relatively favorable side effect profiles...Emerging agents like lumateperone (Dec 2021) and esketamine show promise, while pharmacogenomic research is paving the way for more personalized treatments...However, disparities in medication accessibility between developed and developing countries highlight the need for global collaboration to optimize BD management. Continued research and innovation are essential to addressing the complexities of BD and improving patient outcomes worldwide."

Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Effect of cariprazine on attention and quality of life in patients with predominant negative symptoms of schizophrenia: A post-hoc analysis. (PubMed, Schizophr Res Cogn) - "Differences in CDR-CoA scores were significant for cariprazine vs. placebo in the ITT and PNS analyses; and was significant for aripiprazole vs. placebo in the PNS analysis, but not in the ITT analysis. This post-hoc analysis suggests that cariprazine may be associated with beneficial effects on measures of attention and QoL among patients with schizophrenia, and these effects could be more pronounced among individuals with PNS."

HEOR • Journal • Retrospective data • CNS Disorders • Psychiatry • Schizophrenia

Eros Unleashed: A Case Series of Cariprazine-induced Hypersexuality. (PubMed, Indian J Psychol Med) - No abstract available

Journal

Comparative Efficacy, Safety, and Tolerability of Xanomeline and Trospium Chloride versus Eight Atypical Antipsychotics for the Acute Treatment of Adults with Schizophrenia - A Network Meta-Analysis (ISPOR 2025) - "Xanomeline/trospium demonstrated improved clinical response and reduced weight gain compared with several existing oral antipsychotics."

Retrospective data • Anesthesia • CNS Disorders • Psychiatry • Schizophrenia

Resolution of Catatonia With Cariprazine-A Case Report. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal

Highly sensitive electrochemical determination of cariprazine using a novel Ti3C2@CoAl2O4 nanocomposite: application to pharmaceutical and biological sample analysis. (PubMed, Mikrochim Acta) - "The sensor was successfully applied to human blood serum, urine, and CAR tablets, achieving high recovery values (98.52-103.94%), confirming its reliability for real-sample analysis. These findings underline the novelty and potential of the Ti3C2@CoAl2O2-modified GCE as a powerful tool for the accurate, selective, and sensitive determination of CAR in clinical and pharmaceutical applications."

Journal • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry • Rare Diseases • Schizophrenia

Frequency, correlates and outcomes of Benzodiazepine use during Cariprazine treatment: A pooled post-hoc analysis from four 6-week, placebo-controlled trials in patients with an acute exacerbation of schizophrenia. (PubMed, Eur Neuropsychopharmacol) - "The results support the superior efficacy of CAR with or without BZD co-treatment for total and positive symptoms of schizophrenia compared to PLB with or without BZD use. These findings suggest BZDs should be used for emergent symptoms like anxiety or agitation, rather than core schizophrenia symptoms."

Biomarker • Journal • Retrospective data • CNS Disorders • Mood Disorders • Psychiatry • Schizophrenia

Physical illness in schizophrenia and the role of tolerability in antipsychotic selection: an expert consensus with a focus on cariprazine. (PubMed, Ann Gen Psychiatry) - "The choice of treatment is based primarily on efficacy and tolerability. Cariprazine is beneficial in patients with positive and negative symptoms, and it has a side-effect profile with low rates of metabolic side effects, sedation, and sexual dysfunction."

Journal • Review • Anesthesia • Cardiovascular • CNS Disorders • Psychiatry • Schizophrenia • Sexual Disorders

Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis. (PubMed, Eur Neuropsychopharmacol) - "Dose discontinuation curves varied between the antipsychotics and included U-shaped, monotonic, and hyperbolic patterns. Future studies should consistently present disease-related and side-effect-related dropouts due to adverse events separately."

Journal • Retrospective data • Review • CNS Disorders • Psychiatry • Schizophrenia

EISAI APPROVES ADDITIONAL INDICATION FOR SCHIZOPHRENIA AND BIPOLAR DISORDER TREATMENT "CARIPRAZINE" (MP-214) AS ADDITIONAL TREATMENT FOR MAIN DEPRESSIVE DISORDER IN THAILAND [Google translation] (Mitsubishi Tanabe Press Release) - "Mitsubishi Tanabe Pharma...is pleased to announce that its consolidated subsidiary, Mitsubishi Tanabe Pharma (Thailand) Co., Ltd., received approval on January 31st in Thailand for a new indication for cariprazine (generic name, clinical trial code: MP-214, dopamine D3/D2 receptor partial agonist, Thai product name: Reagila) as adjunctive therapy to antidepressants in the treatment of major depressive disorder."

Approval • Bipolar Disorder • Schizophrenia

AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results (PRNewswire) - "Full-Year Global Net Revenues from the Immunology Portfolio Were $26.682 Billion, an Increase of 2.1 Percent on a Reported Basis, or 2.9 Percent on an Operational Basis; Global Humira Net Revenues Were $8.993 Billion; Global Skyrizi Net Revenues Were $11.718 Billion; Global Rinvoq Net Revenues Were $5.971 Billion...Full-Year Global Net Revenues from the Neuroscience Portfolio Were $8.999 Billion, an Increase of 16.6 Percent on a Reported Basis, or 16.9 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $3.283 Billion; Global Vraylar Net Revenues Were $3.267 Billion; Combined Global Ubrelvy and Qulipta Net Revenues were $1.664 Billion..."

Commercial • Ankylosing Spondylitis • Atopic Dermatitis • Crohn's disease • Hidradenitis Suppurativa • Idiopathic Arthritis • Inflammatory Arthritis • Migraine • Multiple Sclerosis • Ophthalmology • Overactive Bladder • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Schizophrenia • Spondylarthritis • Ulcerative Colitis • Uveitis

Unlocking the molecular mechanisms of anticancer and immunomodulatory potentials of cariprazine in triple negative breast cancer. (PubMed, Biomed Pharmacother) - "This study examined the anticancer effects of the antipsychotics Cariprazine (CAR), Olanzapine (OLZ), and Clozapine (CLZ), and the immunomodulatory potential of CAR, in vitro and in vivo in TNBC models...In conclusion, compared with other antipsychotics, 5-FU, and cisplatin, CAR exerted the most potent anticancer activity in TNBC in vitro and in vivo. This efficacy may be attributed to its ability to regulate apoptosis and autophagy, promote G0/G1 cell cycle arrest, and modulate antitumor immune response, suggesting its therapeutic potential in breast cancer."

Journal • Breast Cancer • CNS Disorders • Oncology • Solid Tumor • Triple Negative Breast Cancer • BAX • BCL2 • BECN1 • CASP3 • CASP9 • CDKN1A • IFNG • IL17A • IL1B • TNFA

The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States. (PubMed, J Med Econ) - "Rates of disability events, days, and mean costs were significantly lower after versus before cariprazine initiation. These results can help contextualize cariprazine's role in managing disability for these patients."

Journal • Real-world evidence • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Schizophrenia

Healthcare resource utilization with adjunctive cariprazine and other atypical antipsychotics in patients with major depressive disorder. (PubMed, Curr Med Res Opin) - "The study included adults with ≥1 inpatient MDD claim or ≥2 outpatient MDD claims >30 days apart and ≥1 claim for cariprazine, brexpiprazole, generic aripiprazole, or generic quetiapine adjunctive to an antidepressant (ie, ≥14-day overlap between AA and antidepressant). All-cause and MDD-related office and psychiatric visits were significantly lower in the cariprazine versus most other AA cohorts. Although causality cannot be determined from these real-world findings, results suggest that in patients with MDD, initiating adjunctive cariprazine is associated with significantly lower HRU for certain outcomes relative to other AAs."

HEOR • Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Pharmacological Treatment of Neuropsychiatric Symptoms in Huntington's Disease: A Systematic Review. (PubMed, Mov Disord Clin Pract) - "We conclude that although NPS in HD are common, hardly any clinical trials have addressed their treatment. As a result, convincing evidence that could guide clinical practice is lacking. More focused, and larger, multicenter trials focusing on NPS are urgently needed to generate the knowledge necessary to support the development of evidence-based clinical treatment guidelines."

Journal • Review • CNS Disorders • Depression • Huntington's Disease • Mood Disorders • Movement Disorders • Psychiatry

Cariprazine for Clozapine-Induced Urinary Incontinence in Treatment-Resistant Depression: A Case Report. (PubMed, Cureus) - "No other medication was altered, and upon reintroduction of cariprazine, the patient's UI improved significantly. Although a single case is inadequate for establishing definitive conclusions, this case report indicates the need for further investigation into the potential of cariprazine in addressing clozapine-induced UI."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Urinary Incontinence • Urology

Seeing beyond the norm: Unveiling ocular complications with atypical antipsychotics. (PubMed, Ind Psychiatry J) - "This case series presents three instances where atypical antipsychotics, namely Risperidone, Cariprazine, and Olanzapine, led to ocular dystonias and nystagmus. The present case series underscores the necessity of vigilant monitoring for ocular adverse effects, even with atypical antipsychotics, given their potential to induce acute dystonias and nystagmus. The presented cases advocate for heightened awareness among clinicians to promptly recognize and manage such rare complications, ensuring optimal patient care and treatment outcomes."

Journal • CNS Disorders • Dystonia • Movement Disorders • Ophthalmology

Effect of Cariprazine on Anhedonia in Patients with Bipolar I Depression: Post Hoc Analysis of Three Randomized Placebo-Controlled Clinical Trials. (PubMed, Adv Ther) - P2, P3 | "Cariprazine demonstrated antidepressant and specific anti-anhedonic effects regardless of baseline anhedonia symptoms in patients with BP-I depression."

Clinical • Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Therapeutic Drug Monitoring of Cariprazine - Updated Values for a Dose-Related Reference Range. (PubMed, Pharmacopsychiatry) - "Accordingly, a lower value of 0.85 and an upper value of 2.31 were calculated for the updated dose-related reference range, which is below the currently recommended values.The results suggest that the current values for the dose-related reference range are too high and require adjustment. The updated dose-related reference range lies between 0.85 and 2.31, with a mean of 1.58±0.73."

Journal • Psychiatry

Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting. (PubMed, Ann Gen Psychiatry) - "In this real-world analysis, cariprazine was associated with an estimated weight gain of + 0.91 kg/year and had minimal impact on BMI and blood pressure when evaluated up to 12 months."

Journal • Real-world evidence • Bipolar Disorder • Cardiovascular • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Schizophrenia

Effect of Cariprazine on Outcomes in Older-aged and Younger-aged Patients with Bipolar I Disorder: A Post-hoc Analysis. (PubMed, Am J Geriatr Psychiatry) - "Cariprazine appears to be effective for both depressive and manic/mixed episodes of bipolar I disorder, regardless of age."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Healthcare resource utilization and costs of using Cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder. (PubMed, J Med Econ) - "Claims were a proxy for cariprazine use. Results from this real‑world study of commercially insured US adults suggest that initiating cariprazine as the first adjunctive therapy rather than a subsequent therapy could help mitigate the considerable economic burden of MDD for appropriate patients."

HEOR • Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry